Santa Farma Pharmaceuticals remains committed to enhancing the visibility of its R&D expertise across international scientific arenas.
The in-vivo bioequivalence study led by our Clinical Trials Department for our product containing the active ingredient Phenyramidol HCl was featured in the "European Journal of Applied Sciences".
This study demonstrates not only the scientific success of a single product, but also Santa Farma Pharmaceuticals' global capability and competitive strength.
As Santa Farma Pharmaceuticals, with our strong R&D infrastructure and international collaborations, we remain committed to bringing innovative products developed in Türkiye to the world and contributing to the global healthcare ecosystem.
